TruScreen Limited (NZAX TRU) would like to advise that at the Company’s annual meeting on 21 September, 2017, Timothy Preston will retire in accordance with the Company’s constitution and the NZAX Listing Rules.
Timothy Preston is eligible and as such offers himself for re-election.
Nominations for directors are now being accepted by the Company. The closing date for nominations is 5pm on Monday, 4 September, 2017.
Director nominations: – can only be made by shareholders who are entitled to attend and vote at the annual meeting; – must be accompanied by the consent, in writing, of the person nominated; – should contain a brief curriculum vitae of the nominee; and – must be received by the Company by 5pm on Monday, 4 September, 2017.
Please send director nominations to:
Email to email@example.com
Or Contact Martin Dillon
TruScreen Chief Executive Officer
For more information visit www.truscreen.com or contact Martin Dillon, TruScreen Chief Executive
Officer, eMail: firstname.lastname@example.org
TruScreen’s real time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissue. A sophisticated proprietary algorithm framework distinguishes between normal and abnormal (cancerous and precancerous) tissue to identify precancerous change, or cervical intraepithelial neoplasia (CIN). A Single Use Sensor (SUS) is used for each patient to protect against cross-infection